FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US

The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data

Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly

The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection

MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners

These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development

Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses

Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics

Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth

Health Minister Mandaviya inaugurates the phase II of Mass Drug Administration initiative for Lymphatic Filariasis

India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive

Mandaviya calls for collaboration to eliminate vector borne diseases

Albumedix and Valneva expand collaboration to include newly approved inactivated Covid-19 vaccine

This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines

Valneva receives funding for Covid-19 vaccine from Scotland

The grants are expected to be received over the next three years, commencing March 2022